Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2011 Jan 28;17(4):459-69. doi: 10.3748/wjg.v17.i4.459.

Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Author information

  • 1Department of Nutrition and Health, Nestlé Research Centre, Vers-chez-les-Blanc, Lausanne 26, Switzerland.



To assess the anti-inflammatory effect of the probiotic Bifidobacterium lactis (B. lactis) in an adoptive transfer model of colitis.


Donor and recipient mice received either B. lactis or bacterial culture medium as control (deMan Rogosa Sharpe) in drinking water for one week prior to transfer of a mix of naive and regulatory T cells until sacrifice.


All recipient mice developed signs of colonic inflammation, but a significant reduction of weight loss was observed in B. lactis-fed recipient mice compared to control mice. Moreover, a trend toward a diminution of mucosal thickness and attenuated epithelial damage was revealed. Colonic expression of pro-inflammatory and T cell markers was significantly reduced in B. lactis-fed recipient mice compared to controls. Concomitantly, forkhead box protein 3, a marker of regulatory T cells, was significantly up-regulated by B. lactis.


Daily oral administration of B. lactis was able to reduce inflammatory and T cells mediators and to promote regulatory T cells specific markers in a mouse model of colitis.


Adoptive transfer model; Bifidobacterium; Colitis; Inflammation; Mice; Probiotics; Regulatory T cells

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk